A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
NCT06772870
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Friedreich Ataxia
Interventions
DRUG:
DT-216P2
DRUG:
Saline
Sponsor
Design Therapeutics, Inc.